Inspired by insights into ISG15 deficiency, researchers at Columbia University engineered an mRNA-based antiviral showing broad activity against diverse viruses including Zika, SARS-CoV-2, and influenza. Published in Science Translational Medicine, the study highlights the potential for this modular platform to serve as a first-line defense against known and emerging viral threats. By harnessing type I interferon-stimulated genes, the therapy balances potent antiviral effects with controlled immune responses, aiming to address current limitations of mRNA vaccine deployment and enhance pandemic preparedness.